<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_medium=rss&amp;fc=20230708114047&amp;ff=20240523100827&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_medium=rss&amp;fc=20230708114047&amp;ff=20240523100827&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 23 May 2024 14:08:28 +0000</lastbuilddate>
<pubDate>Wed, 22 May 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Reply: Intravascular Imaging for Complex Coronary Intervention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38777519/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240523100827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 28;83(21):e209. doi: 10.1016/j.jacc.2024.03.406.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38777519/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240523100827&v=2.18.0.post9+e462414">38777519</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.406>10.1016/j.jacc.2024.03.406</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38777519</guid>
<pubDate>Wed, 22 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Do-Yoon Kang</dc:creator>
<dc:creator>Jung-Min Ahn</dc:creator>
<dc:creator>Seung-Jung Park</dc:creator>
<dc:creator>Duk-Woo Park</dc:creator>
<dc:date>2024-05-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Intravascular Imaging for Complex Coronary Intervention</dc:title>
<dc:identifier>pmid:38777519</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.406</dc:identifier>
</item>
<item>
<title>Intravascular Imaging for Complex Coronary Intervention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38777518/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240523100827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 28;83(21):e207. doi: 10.1016/j.jacc.2024.01.042.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38777518/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240523100827&v=2.18.0.post9+e462414">38777518</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.042>10.1016/j.jacc.2024.01.042</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38777518</guid>
<pubDate>Wed, 22 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Ahmet Güner</dc:creator>
<dc:creator>İbrahim Faruk Aktürk</dc:creator>
<dc:creator>Ahmet Yaşar Çizgici</dc:creator>
<dc:creator>Fatih Uzun</dc:creator>
<dc:date>2024-05-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Intravascular Imaging for Complex Coronary Intervention</dc:title>
<dc:identifier>pmid:38777518</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.042</dc:identifier>
</item>
<item>
<title>Reply: Understanding of Aging Effects on the Clinical Course in Patients With Congenital Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38777517/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240523100827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 28;83(21):e205-e206. doi: 10.1016/j.jacc.2024.03.407.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38777517/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240523100827&v=2.18.0.post9+e462414">38777517</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.407>10.1016/j.jacc.2024.03.407</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38777517</guid>
<pubDate>Wed, 22 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Aditya Sengupta</dc:creator>
<dc:creator>Steven D Colan</dc:creator>
<dc:creator>Meena Nathan</dc:creator>
<dc:date>2024-05-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Understanding of Aging Effects on the Clinical Course in Patients With Congenital Heart Disease</dc:title>
<dc:identifier>pmid:38777517</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.407</dc:identifier>
</item>
<item>
<title>Understanding of Aging Effects on the Clinical Course in Patients With Congenital Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38777516/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240523100827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 28;83(21):e203. doi: 10.1016/j.jacc.2024.02.054.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38777516/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240523100827&v=2.18.0.post9+e462414">38777516</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.054>10.1016/j.jacc.2024.02.054</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38777516</guid>
<pubDate>Wed, 22 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Tomoaki Murakami</dc:creator>
<dc:date>2024-05-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Understanding of Aging Effects on the Clinical Course in Patients With Congenital Heart Disease</dc:title>
<dc:identifier>pmid:38777516</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.054</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38777515/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240523100827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 28;83(21):2133. doi: 10.1016/j.jacc.2024.04.021.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38777515/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240523100827&v=2.18.0.post9+e462414">38777515</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.021>10.1016/j.jacc.2024.04.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38777515</guid>
<pubDate>Wed, 22 May 2024 06:00:00 -0400</pubDate>
<dc:date>2024-05-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:38777515</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.021</dc:identifier>
</item>
<item>
<title>Synergizing Success: The Power of Dyad Leadership in Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38777514/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240523100827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 28;83(21):2128-2129. doi: 10.1016/j.jacc.2024.04.014.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38777514/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240523100827&v=2.18.0.post9+e462414">38777514</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.014>10.1016/j.jacc.2024.04.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38777514</guid>
<pubDate>Wed, 22 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Cathleen Biga</dc:creator>
<dc:date>2024-05-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Synergizing Success: The Power of Dyad Leadership in Cardiology</dc:title>
<dc:identifier>pmid:38777514</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.014</dc:identifier>
</item>
<item>
<title>Personalized Intervention Based on Early Detection of Atherosclerosis: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38777513/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240523100827&amp;v=2.18.0.post9+e462414
      <description>Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide and challenges the capacity of health care systems globally. Atherosclerosis is the underlying pathophysiological entity in two-thirds of patients with CVD. When considering that atherosclerosis develops over decades, there is potentially great opportunity for prevention of associated events such as myocardial infarction and stroke. Subclinical atherosclerosis has been identified in its early stages in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 28;83(21):2112-2127. doi: 10.1016/j.jacc.2024.02.053.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide and challenges the capacity of health care systems globally. Atherosclerosis is the underlying pathophysiological entity in two-thirds of patients with CVD. When considering that atherosclerosis develops over decades, there is potentially great opportunity for prevention of associated events such as myocardial infarction and stroke. Subclinical atherosclerosis has been identified in its early stages in young individuals; however, there is no consensus on how to prevent progression to symptomatic disease. Given the growing burden of CVD, a paradigm shift is required-moving from late management of atherosclerotic CVD to earlier detection during the subclinical phase with the goal of potential cure or prevention of events. Studies must focus on how precision medicine using imaging and circulating biomarkers may identify atherosclerosis earlier and determine whether such a paradigm shift would lead to overall cost savings for global health.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38777513/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240523100827&v=2.18.0.post9+e462414">38777513</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.053>10.1016/j.jacc.2024.02.053</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38777513</guid>
<pubDate>Wed, 22 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Rikke V Nielsen</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:creator>Henning Bundgaard</dc:creator>
<dc:creator>Jose J Fuster</dc:creator>
<dc:creator>Amer M Johri</dc:creator>
<dc:creator>Klaus F Kofoed</dc:creator>
<dc:creator>Pamela S Douglas</dc:creator>
<dc:creator>Axel Diederichsen</dc:creator>
<dc:creator>Michael D Shapiro</dc:creator>
<dc:creator>Stephen J Nicholls</dc:creator>
<dc:creator>Børge G Nordestgaard</dc:creator>
<dc:creator>Jes S Lindholt</dc:creator>
<dc:creator>Calum MacRae</dc:creator>
<dc:creator>Chun Yuan</dc:creator>
<dc:creator>David E Newby</dc:creator>
<dc:creator>Elaine M Urbina</dc:creator>
<dc:creator>Göran Bergström</dc:creator>
<dc:creator>Martin Ridderstråle</dc:creator>
<dc:creator>Matthew J Budoff</dc:creator>
<dc:creator>Morten Bøttcher</dc:creator>
<dc:creator>Olli T Raitakari</dc:creator>
<dc:creator>Thomas H Hansen</dc:creator>
<dc:creator>Ulf Näslund</dc:creator>
<dc:creator>Henrik Sillesen</dc:creator>
<dc:creator>Nikolaj Eldrup</dc:creator>
<dc:creator>Borja Ibanez</dc:creator>
<dc:date>2024-05-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Personalized Intervention Based on Early Detection of Atherosclerosis: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:38777513</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.053</dc:identifier>
</item>
<item>
<title>Clinical Risk Assessment and Prediction in Congenital Heart Disease Across the Lifespan: JACC Scientific Statement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38777512/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240523100827&amp;v=2.18.0.post9+e462414
      <description>Congenital heart disease (CHD) comprises a range of structural anomalies, each with a unique natural history, evolving treatment strategies, and distinct long-term consequences. Current prediction models are challenged by generalizability, limited validation, and questionable application to extended follow-up periods. In this JACC Scientific Statement, we tackle the difficulty of risk measurement across the lifespan. We appraise current and future risk measurement frameworks and describe domains...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 28;83(21):2092-2111. doi: 10.1016/j.jacc.2024.02.055.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Congenital heart disease (CHD) comprises a range of structural anomalies, each with a unique natural history, evolving treatment strategies, and distinct long-term consequences. Current prediction models are challenged by generalizability, limited validation, and questionable application to extended follow-up periods. In this JACC Scientific Statement, we tackle the difficulty of risk measurement across the lifespan. We appraise current and future risk measurement frameworks and describe domains of risk specific to CHD. Risk of adverse outcomes varies with age, sex, genetics, era, socioeconomic status, behavior, and comorbidities as they evolve through the lifespan and across care settings. Emerging technologies and approaches promise to improve risk assessment, but there is also need for large, longitudinal, representative, prospective CHD cohorts with multidimensional data and consensus-driven methodologies to provide insight into time-varying risk. Communication of risk, particularly with patients and their families, poses a separate and equally important challenge, and best practices are reviewed.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38777512/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240523100827&v=2.18.0.post9+e462414">38777512</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.055>10.1016/j.jacc.2024.02.055</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38777512</guid>
<pubDate>Wed, 22 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Alexander R Opotowsky</dc:creator>
<dc:creator>Paul Khairy</dc:creator>
<dc:creator>Gerhard Diller</dc:creator>
<dc:creator>Nadine A Kasparian</dc:creator>
<dc:creator>James Brophy</dc:creator>
<dc:creator>Kathy Jenkins</dc:creator>
<dc:creator>Keila N Lopez</dc:creator>
<dc:creator>Alison McCoy</dc:creator>
<dc:creator>Philip Moons</dc:creator>
<dc:creator>Nicholas J Ollberding</dc:creator>
<dc:creator>Rahul H Rathod</dc:creator>
<dc:creator>Jack Rychik</dc:creator>
<dc:creator>George Thanassoulis</dc:creator>
<dc:creator>Ramachandran S Vasan</dc:creator>
<dc:creator>Ariane Marelli</dc:creator>
<dc:date>2024-05-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Clinical Risk Assessment and Prediction in Congenital Heart Disease Across the Lifespan: JACC Scientific Statement</dc:title>
<dc:identifier>pmid:38777512</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.055</dc:identifier>
</item>
<item>
<title>Over-the-Counter Statins: Revisited After a Generation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38777511/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240523100827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 28;83(21):2089-2091. doi: 10.1016/j.jacc.2024.03.412.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38777511/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240523100827&v=2.18.0.post9+e462414">38777511</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.412>10.1016/j.jacc.2024.03.412</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38777511</guid>
<pubDate>Wed, 22 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Carl E Orringer</dc:creator>
<dc:date>2024-05-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Over-the-Counter Statins: Revisited After a Generation</dc:title>
<dc:identifier>pmid:38777511</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.412</dc:identifier>
</item>
<item>
<title>Hemorrhagic Myocardial Infarction: Light After 50 Years in the Tunnel</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38777510/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240523100827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 28;83(21):2063-2065. doi: 10.1016/j.jacc.2024.03.413.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38777510/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240523100827&v=2.18.0.post9+e462414">38777510</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.413>10.1016/j.jacc.2024.03.413</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38777510</guid>
<pubDate>Wed, 22 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Rohan Dharmakumar</dc:creator>
<dc:creator>Andreas Kumar</dc:creator>
<dc:date>2024-05-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Hemorrhagic Myocardial Infarction: Light After 50 Years in the Tunnel</dc:title>
<dc:identifier>pmid:38777510</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.413</dc:identifier>
</item>
<item>
<title>Clinical Outcomes Associated With Various Microvascular Injury Patterns Identified by CMR After STEMI</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38777509/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240523100827&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: MVI is associated with future adverse outcomes only in patients with a hemorrhagic phenotype (IMH+). Patients with only MVO (MVO+/IMH-) had a prognosis similar to patients without MVI (MVO-/IMH-). This highlights the independent prognostic importance of IMH in assessing and managing risk after STEMI.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 28;83(21):2052-2062. doi: 10.1016/j.jacc.2024.03.408.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The prognostic significance of various microvascular injury (MVI) patterns after ST-segment elevation myocardial infarction (STEMI) is not well known.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to investigate the prognostic implications of different MVI patterns in STEMI patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The authors analyzed 1,109 STEMI patients included in 3 prospective studies. Cardiac magnetic resonance (CMR) was performed 3 days (Q1-Q3: 2-5 days) after percutaneous coronary intervention (PCI) and included late gadolinium enhancement imaging for microvascular obstruction (MVO) and T2∗ mapping for intramyocardial hemorrhage (IMH). Patients were categorized into those without MVI (MVO-/IMH-), those with MVO but no IMH (MVO+/IMH-), and those with IMH (IMH+).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: MVI occurred in 633 (57%) patients, of whom 274 (25%) had an MVO+/IMH- pattern and 359 (32%) had an IMH+ pattern. Infarct size was larger and ejection fraction lower in IMH+ than in MVO+/IMH- and MVO-/IMH- (infarct size: 27% vs 19% vs 18% [P &lt; 0.001]; ejection fraction: 45% vs 50% vs 54% [P &lt; 0.001]). During a median follow-up of 12 months (Q1-Q3: 12-35 months), a clinical outcome event occurred more frequently in IMH+ than in MVO+/IMH- and MVO-/IMH- subgroups (19.5% vs 3.6% vs 4.4%; P &lt; 0.001). IMH+ was the sole independent MVI parameter predicting major adverse cardiovascular events (HR: 3.88; 95% CI: 1.93-7.80; P &lt; 0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: MVI is associated with future adverse outcomes only in patients with a hemorrhagic phenotype (IMH+). Patients with only MVO (MVO+/IMH-) had a prognosis similar to patients without MVI (MVO-/IMH-). This highlights the independent prognostic importance of IMH in assessing and managing risk after STEMI.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38777509/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240523100827&v=2.18.0.post9+e462414">38777509</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.408>10.1016/j.jacc.2024.03.408</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38777509</guid>
<pubDate>Wed, 22 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Ivan Lechner</dc:creator>
<dc:creator>Martin Reindl</dc:creator>
<dc:creator>Thomas Stiermaier</dc:creator>
<dc:creator>Christina Tiller</dc:creator>
<dc:creator>Magdalena Holzknecht</dc:creator>
<dc:creator>Fritz Oberhollenzer</dc:creator>
<dc:creator>Sebastian von der Emde</dc:creator>
<dc:creator>Agnes Mayr</dc:creator>
<dc:creator>Hans-Josef Feistritzer</dc:creator>
<dc:creator>Jaclyn Carberry</dc:creator>
<dc:creator>David Carrick</dc:creator>
<dc:creator>Axel Bauer</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:creator>Colin Berry</dc:creator>
<dc:creator>Ingo Eitel</dc:creator>
<dc:creator>Bernhard Metzler</dc:creator>
<dc:creator>Sebastian J Reinstadler</dc:creator>
<dc:date>2024-05-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Clinical Outcomes Associated With Various Microvascular Injury Patterns Identified by CMR After STEMI</dc:title>
<dc:identifier>pmid:38777509</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.408</dc:identifier>
</item>
<item>
<title>Finding an Unobstructed View Toward the Treatment of Nonobstructive Hypertrophic Cardiomyopathy: Lifting the Hunger Fog</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38777508/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240523100827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 28;83(21):2049-2051. doi: 10.1016/j.jacc.2024.04.006.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38777508/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240523100827&v=2.18.0.post9+e462414">38777508</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.006>10.1016/j.jacc.2024.04.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38777508</guid>
<pubDate>Wed, 22 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Amrut V Ambardekar</dc:creator>
<dc:creator>Benjamin J Kopecky</dc:creator>
<dc:creator>David S Raymer</dc:creator>
<dc:date>2024-05-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Finding an Unobstructed View Toward the Treatment of Nonobstructive Hypertrophic Cardiomyopathy: Lifting the Hunger Fog</dc:title>
<dc:identifier>pmid:38777508</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.006</dc:identifier>
</item>
<item>
<title>Global epistasis and the emergence of function in microbial consortia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38776921/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240523100827&amp;v=2.18.0.post9+e462414
      <description>The many functions of microbial communities emerge from a complex web of interactions between organisms and their environment. This poses a significant obstacle to engineering microbial consortia, hindering our ability to harness the potential of microorganisms for biotechnological applications. In this study, we demonstrate that the collective effect of ecological interactions between microbes in a community can be captured by simple statistical models that predict how adding a new species to a...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 14:S0092-8674(24)00411-2. doi: 10.1016/j.cell.2024.04.016. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The many functions of microbial communities emerge from a complex web of interactions between organisms and their environment. This poses a significant obstacle to engineering microbial consortia, hindering our ability to harness the potential of microorganisms for biotechnological applications. In this study, we demonstrate that the collective effect of ecological interactions between microbes in a community can be captured by simple statistical models that predict how adding a new species to a community will affect its function. These predictive models mirror the patterns of global epistasis reported in genetics, and they can be quantitatively interpreted in terms of pairwise interactions between community members. Our results illuminate an unexplored path to quantitatively predicting the function of microbial consortia from their composition, paving the way to optimizing desirable community properties and bringing the tasks of predicting biological function at the genetic, organismal, and ecological scales under the same quantitative formalism.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38776921/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240523100827&v=2.18.0.post9+e462414">38776921</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.016>10.1016/j.cell.2024.04.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38776921</guid>
<pubDate>Wed, 22 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Juan Diaz-Colunga</dc:creator>
<dc:creator>Abigail Skwara</dc:creator>
<dc:creator>Jean C C Vila</dc:creator>
<dc:creator>Djordje Bajic</dc:creator>
<dc:creator>Alvaro Sanchez</dc:creator>
<dc:date>2024-05-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Global epistasis and the emergence of function in microbial consortia</dc:title>
<dc:identifier>pmid:38776921</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.016</dc:identifier>
</item>
<item>
<title>Human inherited CCR2 deficiency underlies progressive polycystic lung disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38776920/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240523100827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 21:S0092-8674(24)00530-0. doi: 10.1016/j.cell.2024.05.021. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38776920/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240523100827&v=2.18.0.post9+e462414">38776920</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.021>10.1016/j.cell.2024.05.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38776920</guid>
<pubDate>Wed, 22 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Anna-Lena Neehus</dc:creator>
<dc:creator>Brenna Carey</dc:creator>
<dc:creator>Marija Landekic</dc:creator>
<dc:creator>Patricia Panikulam</dc:creator>
<dc:creator>Gail Deutsch</dc:creator>
<dc:creator>Masato Ogishi</dc:creator>
<dc:creator>Carlos A Arango-Franco</dc:creator>
<dc:creator>Quentin Philippot</dc:creator>
<dc:creator>Mohammadreza Modaresi</dc:creator>
<dc:creator>Iraj Mohammadzadeh</dc:creator>
<dc:creator>Melissa Corcini Berndt</dc:creator>
<dc:creator>Darawan Rinchai</dc:creator>
<dc:creator>Tom Le Voyer</dc:creator>
<dc:creator>Jérémie Rosain</dc:creator>
<dc:creator>Mana Momenilandi</dc:creator>
<dc:creator>Marta Martin-Fernandez</dc:creator>
<dc:creator>Taushif Khan</dc:creator>
<dc:creator>Jonathan Bohlen</dc:creator>
<dc:creator>Ji Eun Han</dc:creator>
<dc:creator>Alexandre Deslys</dc:creator>
<dc:creator>Mathilde Bernard</dc:creator>
<dc:creator>Tania Gajardo-Carrasco</dc:creator>
<dc:creator>Camille Soudée</dc:creator>
<dc:creator>Corentin Le Floc'h</dc:creator>
<dc:creator>Mélanie Migaud</dc:creator>
<dc:creator>Yoann Seeleuthner</dc:creator>
<dc:creator>Mi-Sun Jang</dc:creator>
<dc:creator>Eirini Nikolouli</dc:creator>
<dc:creator>Simin Seyedpour</dc:creator>
<dc:creator>Hugues Begueret</dc:creator>
<dc:creator>Jean-François Emile</dc:creator>
<dc:creator>Pierre Le Guen</dc:creator>
<dc:creator>Guido Tavazzi</dc:creator>
<dc:creator>Costanza Natalia Julia Colombo</dc:creator>
<dc:creator>Federico Capra Marzani</dc:creator>
<dc:creator>Micol Angelini</dc:creator>
<dc:creator>Francesca Trespidi</dc:creator>
<dc:creator>Stefano Ghirardello</dc:creator>
<dc:creator>Nasrin Alipour</dc:creator>
<dc:creator>Anne Molitor</dc:creator>
<dc:creator>Raphael Carapito</dc:creator>
<dc:creator>Mohsen Mazloomrezaei</dc:creator>
<dc:creator>Hassan Rokni-Zadeh</dc:creator>
<dc:creator>Majid Changi-Ashtiani</dc:creator>
<dc:creator>Chantal Brouzes</dc:creator>
<dc:creator>Pablo Vargas</dc:creator>
<dc:creator>Alessandro Borghesi</dc:creator>
<dc:creator>Nico Lachmann</dc:creator>
<dc:creator>Seiamak Bahram</dc:creator>
<dc:creator>Bruno Crestani</dc:creator>
<dc:creator>Michael Fayon</dc:creator>
<dc:creator>François Galode</dc:creator>
<dc:creator>Susanta Pahari</dc:creator>
<dc:creator>Larry S Schlesinger</dc:creator>
<dc:creator>Nico Marr</dc:creator>
<dc:creator>Dusan Bogunovic</dc:creator>
<dc:creator>Stéphanie Boisson-Dupuis</dc:creator>
<dc:creator>Vivien Béziat</dc:creator>
<dc:creator>Laurent Abel</dc:creator>
<dc:creator>Raphael Borie</dc:creator>
<dc:creator>Lisa R Young</dc:creator>
<dc:creator>Robin Deterding</dc:creator>
<dc:creator>Mohammad Shahrooei</dc:creator>
<dc:creator>Nima Rezaei</dc:creator>
<dc:creator>Nima Parvaneh</dc:creator>
<dc:creator>Daniel Craven</dc:creator>
<dc:creator>Philippe Gros</dc:creator>
<dc:creator>Danielle Malo</dc:creator>
<dc:creator>Fernando E Sepulveda</dc:creator>
<dc:creator>Lawrence M Nogee</dc:creator>
<dc:creator>Nathalie Aladjidi</dc:creator>
<dc:creator>Bruce C Trapnell</dc:creator>
<dc:creator>Jean-Laurent Casanova</dc:creator>
<dc:creator>Jacinta Bustamante</dc:creator>
<dc:date>2024-05-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Human inherited CCR2 deficiency underlies progressive polycystic lung disease</dc:title>
<dc:identifier>pmid:38776920</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.021</dc:identifier>
</item>
<item>
<title>A genomic compendium of cultivated human gut fungi characterizes the gut mycobiome and its relevance to common diseases</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38776919/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240523100827&amp;v=2.18.0.post9+e462414
      <description>The gut fungal community represents an essential element of human health, yet its functional and metabolic potential remains insufficiently elucidated, largely due to the limited availability of reference genomes. To address this gap, we presented the cultivated gut fungi (CGF) catalog, encompassing 760 fungal genomes derived from the feces of healthy individuals. This catalog comprises 206 species spanning 48 families, including 69 species previously unidentified. We explored the functional and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 14:S0092-8674(24)00469-0. doi: 10.1016/j.cell.2024.04.043. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The gut fungal community represents an essential element of human health, yet its functional and metabolic potential remains insufficiently elucidated, largely due to the limited availability of reference genomes. To address this gap, we presented the cultivated gut fungi (CGF) catalog, encompassing 760 fungal genomes derived from the feces of healthy individuals. This catalog comprises 206 species spanning 48 families, including 69 species previously unidentified. We explored the functional and metabolic attributes of the CGF species and utilized this catalog to construct a phylogenetic representation of the gut mycobiome by analyzing over 11,000 fecal metagenomes from Chinese and non-Chinese populations. Moreover, we identified significant common disease-related variations in gut mycobiome composition and corroborated the associations between fungal signatures and inflammatory bowel disease (IBD) through animal experimentation. These resources and findings substantially enrich our understanding of the biological diversity and disease relevance of the human gut mycobiome.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38776919/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240523100827&v=2.18.0.post9+e462414">38776919</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.043>10.1016/j.cell.2024.04.043</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38776919</guid>
<pubDate>Wed, 22 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Qiulong Yan</dc:creator>
<dc:creator>Shenghui Li</dc:creator>
<dc:creator>Qingsong Yan</dc:creator>
<dc:creator>Xiaokui Huo</dc:creator>
<dc:creator>Chao Wang</dc:creator>
<dc:creator>Xifan Wang</dc:creator>
<dc:creator>Yan Sun</dc:creator>
<dc:creator>Wenyu Zhao</dc:creator>
<dc:creator>Zhenlong Yu</dc:creator>
<dc:creator>Yue Zhang</dc:creator>
<dc:creator>Ruochun Guo</dc:creator>
<dc:creator>Qingbo Lv</dc:creator>
<dc:creator>Xin He</dc:creator>
<dc:creator>Changliang Yao</dc:creator>
<dc:creator>Zhiming Li</dc:creator>
<dc:creator>Fang Chen</dc:creator>
<dc:creator>Qianru Ji</dc:creator>
<dc:creator>Aiqin Zhang</dc:creator>
<dc:creator>Hao Jin</dc:creator>
<dc:creator>Guangyang Wang</dc:creator>
<dc:creator>Xiaoying Feng</dc:creator>
<dc:creator>Lei Feng</dc:creator>
<dc:creator>Fan Wu</dc:creator>
<dc:creator>Jing Ning</dc:creator>
<dc:creator>Sa Deng</dc:creator>
<dc:creator>Yue An</dc:creator>
<dc:creator>De-An Guo</dc:creator>
<dc:creator>Francis M Martin</dc:creator>
<dc:creator>Xiaochi Ma</dc:creator>
<dc:date>2024-05-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A genomic compendium of cultivated human gut fungi characterizes the gut mycobiome and its relevance to common diseases</dc:title>
<dc:identifier>pmid:38776919</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.043</dc:identifier>
</item>
<item>
<title>Transcatheter or Surgical Replacement for Failed Bioprosthetic Aortic Valves</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38776106/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240523100827&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Compared with redo SAVR, ViV-TAVR was associated with a lower incidence of periprocedural complications and a similar incidence of all-cause mortality through 2 years' follow-up. However, ViV-TAVR was associated with higher rates of late mortality and heart failure hospitalization. These findings may be influenced by residual confounding and require adjudication in a randomized clinical trial.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 May 22. doi: 10.1001/jamacardio.2024.1049. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The use of valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) has been rapidly expanding as an alternative treatment to redo surgical aortic valve replacement (SAVR) for failed bioprosthetic valves despite limited long-term data.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess mortality and morbidity in patients undergoing intervention for failed bioprosthetic SAVR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective population-based cohort analysis conducted between January 1, 2015, and December 31, 2020, with a median (IQR) follow-up time of 2.3 (1.1-4.0) years. A total of 1771 patients with a history of bioprosthetic SAVR who underwent ViV-TAVR or redo SAVR in California, New York, and New Jersey were included. Data were obtained from the California Department of Health Care Access and Information, the New York Statewide Planning and Research Cooperative System, and the New Jersey Discharge Data Collection System. Exclusion criteria included undergoing TAVR or redo SAVR within 5 years from initial SAVR, as well as infective endocarditis, concomitant surgical procedures, and out-of-state residency. Propensity matching yielded 375 patient pairs. Data were analyzed from January to December 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: ViV-TAVR vs redo SAVR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASUREMENTS: The primary outcome was all-cause mortality. Secondary outcomes were stroke, heart failure hospitalization, reoperation, major bleeding, acute kidney failure, new pacemaker insertion, and infective endocarditis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: From 2015 through 2020, the proportion of patients undergoing ViV-TAVR vs redo SAVR increased from 159 of 451 (35.3%) to 498 or 797 (62.5%). Of 1771 participants, 653 (36.9%) were female, and the mean (SD) age was 74.4 (11.3) years. Periprocedural mortality and stroke rates were similar between propensity-matched groups. The ViV-TAVR group had lower periprocedural rates of major bleeding (2.4% vs 5.1%; P = .05), acute kidney failure (1.3% vs 7.2%; P &lt; .001), and new pacemaker implantations (3.5% vs 10.9%; P &lt; .001). The 5-year all-cause mortality rate was 23.4% (95% CI, 15.7-34.1) in the ViV-TAVR group and 13.3% (95% CI, 9.2-18.9) in the redo SAVR group. In a landmark analysis, no difference in mortality was observed up to 2 years (hazard ratio, 1.03; 95% CI, 0.59-1.78), but after 2 years, ViV-TAVR was associated with higher mortality (hazard ratio, 2.97; 95% CI, 1.18-7.47) as well as with a higher incidence of heart failure hospitalization (hazard ratio, 3.81; 95% CI, 1.57-9.22). There were no differences in 5-year incidence of stroke, reoperation, major bleeding, or infective endocarditis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Compared with redo SAVR, ViV-TAVR was associated with a lower incidence of periprocedural complications and a similar incidence of all-cause mortality through 2 years' follow-up. However, ViV-TAVR was associated with higher rates of late mortality and heart failure hospitalization. These findings may be influenced by residual confounding and require adjudication in a randomized clinical trial.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38776106/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240523100827&v=2.18.0.post9+e462414">38776106</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1049>10.1001/jamacardio.2024.1049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38776106</guid>
<pubDate>Wed, 22 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Jessica H Tran</dc:creator>
<dc:creator>Shinobu Itagaki</dc:creator>
<dc:creator>Qi Zeng</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Patrick T O'Gara</dc:creator>
<dc:creator>Michael J Mack</dc:creator>
<dc:creator>A Marc Gillinov</dc:creator>
<dc:creator>Ismail El-Hamamsy</dc:creator>
<dc:creator>Gilbert H L Tang</dc:creator>
<dc:creator>Takahisa Mikami</dc:creator>
<dc:creator>Emilia Bagiella</dc:creator>
<dc:creator>Alan J Moskowitz</dc:creator>
<dc:creator>David H Adams</dc:creator>
<dc:creator>Annetine C Gelijns</dc:creator>
<dc:creator>Michael A Borger</dc:creator>
<dc:creator>Natalia N Egorova</dc:creator>
<dc:date>2024-05-22</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Transcatheter or Surgical Replacement for Failed Bioprosthetic Aortic Valves</dc:title>
<dc:identifier>pmid:38776106</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1049</dc:identifier>
</item>
<item>
<title>Management Challenges for Bioprosthetic Aortic Valve Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38776100/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240523100827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 May 22. doi: 10.1001/jamacardio.2024.1041. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38776100/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240523100827&v=2.18.0.post9+e462414">38776100</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1041>10.1001/jamacardio.2024.1041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38776100</guid>
<pubDate>Wed, 22 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Vinay Guduguntla</dc:creator>
<dc:creator>Robert O Bonow</dc:creator>
<dc:date>2024-05-22</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Management Challenges for Bioprosthetic Aortic Valve Failure</dc:title>
<dc:identifier>pmid:38776100</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1041</dc:identifier>
</item>
<item>
<title>Dual vs Single Cardioversion of Atrial Fibrillation in Patients With Obesity: A Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38776097/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240523100827&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In patients with obesity (BMI ≥35) undergoing electrical cardioversion for atrial fibrillation, dual DCCV results in greater cardioversion success compared with single DCCV, without any increase in complications or patient discomfort.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 May 22. doi: 10.1001/jamacardio.2024.1091. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Atrial fibrillation and obesity are common, and both are increasing in prevalence. Obesity is associated with failure of cardioversion of atrial fibrillation using a standard single set of defibrillator pads, even at high output.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To compare the efficacy and safety of dual direct-current cardioversion (DCCV) using 2 sets of pads, with each pair simultaneously delivering 200 J, with traditional single 200-J DCCV using 1 set of pads in patients with obesity and atrial fibrillation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a prospective, investigator-initiated, patient-blinded, randomized clinical trial spanning 3 years from August 2020 to 2023. As a multicenter trial, the setting included 3 sites in Louisiana. Eligibility criteria included body mass index (BMI) of 35 or higher (calculated as weight in kilograms divided by height in meters squared), age 18 years or older, and planned nonemergent electrical cardioversion for atrial fibrillation. Patients who met inclusion criteria were randomized 1:1. Exclusions occurred due to spontaneous cardioversion, instability, thrombus, or BMI below threshold.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Dual DCCV vs single DCCV.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Return to sinus rhythm, regardless of duration, immediately after the first cardioversion attempt of atrial fibrillation, adverse cardiovascular events, and chest discomfort after the procedure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 2079 sequential patients undergoing cardioversion, 276 met inclusion criteria and were approached for participation. Of these, 210 participants were randomized 1:1. After exclusions, 200 patients (median [IQR] age, 67.6 [60.1-72.4] years; 127 male [63.5%]) completed the study. The mean (SD) BMI was 41.2 (6.5). Cardioversion was successful more often with dual DCCV compared with single DCCV (97 of 99 patients [98%] vs 87 of 101 patients [86%]; P = .002). Dual cardioversion predicted success (odds ratio, 6.7; 95% CI, 3.3-13.6; P = .01). Patients in the single cardioversion cohort whose first attempt failed underwent dual cardioversion with all subsequent attempts (up to 3 total), all of which were successful: 12 of 14 after second cardioversion and 2 of 14 after third cardioversion. There was no difference in the rating of postprocedure chest discomfort (median in both groups = 0 of 10; P = .40). There were no cardiovascular complications.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In patients with obesity (BMI ≥35) undergoing electrical cardioversion for atrial fibrillation, dual DCCV results in greater cardioversion success compared with single DCCV, without any increase in complications or patient discomfort.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04539158.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38776097/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240523100827&v=2.18.0.post9+e462414">38776097</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1091>10.1001/jamacardio.2024.1091</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38776097</guid>
<pubDate>Wed, 22 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Joshua D Aymond</dc:creator>
<dc:creator>Alexandra M Sanchez</dc:creator>
<dc:creator>Michael R Castine</dc:creator>
<dc:creator>Michael L Bernard</dc:creator>
<dc:creator>Sammy Khatib</dc:creator>
<dc:creator>A Elise Hiltbold</dc:creator>
<dc:creator>Glenn M Polin</dc:creator>
<dc:creator>Paul A Rogers</dc:creator>
<dc:creator>Paari S Dominic</dc:creator>
<dc:creator>Cruz Velasco-Gonzalez</dc:creator>
<dc:creator>Daniel P Morin</dc:creator>
<dc:date>2024-05-22</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Dual vs Single Cardioversion of Atrial Fibrillation in Patients With Obesity: A Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38776097</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1091</dc:identifier>
</item>
<item>
<title>Change to Open Access Status</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38776071/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240523100827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 May 22. doi: 10.1001/jamacardio.2024.1234. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38776071/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240523100827&v=2.18.0.post9+e462414">38776071</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1234>10.1001/jamacardio.2024.1234</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38776071</guid>
<pubDate>Wed, 22 May 2024 06:00:00 -0400</pubDate>
<dc:date>2024-05-22</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Change to Open Access Status</dc:title>
<dc:identifier>pmid:38776071</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1234</dc:identifier>
</item>
<item>
<title>Error in Figure 4</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38776069/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240523100827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 May 22. doi: 10.1001/jamacardio.2024.1279. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38776069/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240523100827&v=2.18.0.post9+e462414">38776069</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1279>10.1001/jamacardio.2024.1279</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38776069</guid>
<pubDate>Wed, 22 May 2024 06:00:00 -0400</pubDate>
<dc:date>2024-05-22</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Error in Figure 4</dc:title>
<dc:identifier>pmid:38776069</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1279</dc:identifier>
</item>
<item>
<title>Artificially transplanted mitochondria in endothelial cells promote mitophagy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38773356/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240523100827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 May 21. doi: 10.1038/s41569-024-01041-x. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38773356/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240523100827&v=2.18.0.post9+e462414">38773356</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01041-x>10.1038/s41569-024-01041-x</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38773356</guid>
<pubDate>Tue, 21 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2024-05-21</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Artificially transplanted mitochondria in endothelial cells promote mitophagy</dc:title>
<dc:identifier>pmid:38773356</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01041-x</dc:identifier>
</item>





























</channel>
</rss>